Skip to main content

10 Result(s)

within C Gasparetto Remove this filter

and

  1. No Access

    Article

    Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time

    Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM) particularly for upfront autologous hematopoietic cell transplant (AHCT) recipients. We hypothesized that new dr...

    S K Kumar, A Dispenzieri, R Fraser, F Mingwei, G Akpek, R Cornell… in Leukemia (2018)

  2. No Access

    Article

    High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma

    Single-agent high-dose melphalan (HDM, 200 mg/m2) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator...

    D Sivaraj, W Bacon, G D Long, D A Rizzieri, M E Horwitz… in Bone Marrow Transplantation (2018)

  3. No Access

    Article

    Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment

    High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is referred to as pre-engraftment syndrome (PES). Few studi...

    J Kanda, L Kaynar, Y Kanda, V K Prasad, S H Parikh, L Lan… in Bone Marrow Transplantation (2013)

  4. No Access

    Article

    Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

    Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of preemptive plerixafor use following assessment of the peak...

    M E Horwitz, J P Chute, C Gasparetto, G D Long, C McDonald… in Bone Marrow Transplantation (2012)

  5. No Access

    Article

    Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors

    The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiv...

    D-F Chen, V K Prasad, G Broadwater, N L Reinsmoen… in Bone Marrow Transplantation (2012)

  6. No Access

    Article

    Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation

    Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of surviv...

    J Kanda, M E Horwitz, G D Long, C Gasparetto, K M Sullivan… in Bone Marrow Transplantation (2012)

  7. No Access

    Article

    Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

    This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib...

    S K Kumar, I Flinn, S J Noga, P Hari, R Rifkin, N Callander, M Bhandari… in Leukemia (2010)

  8. No Access

    Article

    Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3–6/6 HLA matched donors

    We report the outcome of early donor lymphocyte infusions (DLIs) after T-cell depleted non-myeloablative transplantation using stem cells from HLA-matched or mismatched donors. Sixty-nine patients with high-ri...

    D A Rizzieri, P Dev, G D Long, C Gasparetto, K M Sullivan… in Bone Marrow Transplantation (2009)

  9. No Access

    Article

    Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection

    Following initial graft rejection, a second attempt at allogeneic immunotherapy is often contemplated, but data on the success is limited. We therefore report on 11 patients with hematologic malignancies, rena...

    B J Byrne, M Horwitz, G D Long, C Gasparetto, K M Sullivan… in Bone Marrow Transplantation (2008)

  10. No Access

    Article

    Bioethics, the Surviving Sepsis Campaign and the industry

    J. Bion, J. L. Vincent, P. Angood, A. Malliani… in Wiener klinische Wochenschrift (2006)